

**Louisiana Department of Health  
Medicaid Pharmaceutical and Therapeutics Committee  
628 North Fourth Street  
Baton Rouge, LA  
Bienville Building, Room #118  
April 26, 2024  
9:00 AM  
*Draft***

- I. Call to Order.....Ben Orlando
- II. Parliamentary Business ..... Ben Orlando
  - A. Introduction of Members/Roll Call
  - B. Attendance/Additional Meetings
  - C. Approval of November 4, 2022 Meeting Minutes
- III. Introduction Undersecretary Michael Harrington
- IV. P & T Committee Review Virtual Process.....Hind Douiki
- V. Ethics.....Haley Williams
- VI. Reports.....Sue Fontenot
  - A. PDL Reflecting Fall 2023 Recommendations
  - B. PDL Reporting
- VII. New Business.....Hind Douiki
  - A. Explanation of TOP\$, Monographs and Cost Sheets
  - B. Therapeutic Class Reviews /Public Testimony
    - 1. Acne Agents, Topical
    - 2. Analgesics, Narcotics Long
    - 3. Analgesics, Narcotics Short
    - 4. Androgenic Agents
    - 5. Angiotensin Modulator Combinations
    - 6. Angiotensin Modulators
    - 7. Antibiotics, GI
    - 8. Antibiotics, Inhaled
    - 9. Antibiotics, Topical
    - 10. Antibiotics, Vaginal
    - 11. Anticoagulants
    - 12. Antiemetic/Antivertigo Agents
    - 13. Antifungals, Oral
    - 14. Antifungals, Topical
    - 15. Antimigraine Agents, Other
    - 16. Antimigraine Agents, Triptans
    - 17. Antiparasitics, Topical
    - 18. Antivirals, Oral

19. Antivirals, Topical
20. Beta-Blockers
21. Bladder Relaxant Preparations
22. Bone Resorption Suppression and Related Agents
23. BPH Treatments
24. Calcium Channel Blockers
25. Cephalosporins and Related Antibiotics
26. Cystic Fibrosis, Oral
27. Fluoroquinolones, Oral
28. GI Motility, Chronic
29. Glucagon Agents
30. Growth Factors
31. Growth Hormone
32. H. Pylori Treatment
33. HAE Treatments
34. Hepatitis C Agents
35. HIV/AIDS
36. Hypoglycemics, Alpha-Glucosidase Inhibitors
37. Hypoglycemics, Incretin Mimetics/Enhancers
38. Hypoglycemics, Insulin and Related Agents
39. Hypoglycemics, Meglitinides
40. Hypoglycemics, Metformins
41. Hypoglycemics, SGLT2
42. Hypoglycemics, Sulfonylureas
43. Hypoglycemics, TZD
44. Immunosuppressives, Oral
45. Lincosamides/Oxazolidinones/Streptogramins
46. Lipotropics, Other
47. Lipotropics, Statins
48. Macrolides/Ketolides
49. Multiple Sclerosis Agents
50. Nitrofurans Derivatives
51. Opiate Dependence Treatments
52. PAH Agents, Oral and Inhaled
53. Pancreatic Enzymes
54. Pediatric Vitamin Preparations
55. Phosphate Binders
56. Pituitary Suppressive Agents, LHRH
57. Platelet Aggregation Inhibitors
58. Potassium Binders
59. Proton Pump Inhibitors
60. Sinus Node Inhibitors
61. Skeletal Muscle Relaxants
62. Tetracyclines
63. Ulcerative Colitis Agents
64. Uterine Disorder Treatments
65. Vasodilators, Coronary

C. Hepatitis C Treatment Agents

VIII. New & Other Single Drug Reviews.....Hind Douiki

66. Anticonvulsants – Motpoly XR
67. Anticonvulsants - Rufinamide Tablet and Suspension
68. Anticonvulsants – Divalproex Sprinkle
69. Antidepressants, Other – Zurzuvae
70. Cytokine and Cam Antagonists – Adalimumab – ADBM Kit and Pen Kit
71. Cytokine and Cam Antagonists – Abrilada Kit and Pen Kit
72. Cytokine and Cam Antagonists – Amjevita Kit and Pen Kit
73. Cytokine and Cam Antagonists – Bimzelx Pen and Syringe
74. Cytokine and Cam Antagonists – Cosentyx Vial
75. Cytokine and Cam Antagonists – Entyvio Pen
76. Cytokine and Cam Antagonists – Omvoh Pen and Vial
77. Cytokine and Cam Antagonists - Velsipity
78. Cytokine and Cam Antagonists – Yuflyma Pen Kit
79. Hemophilia Treatment – Balfaxar
80. Immunomodulators, Atopic Dermatitis – Zoryve Foam
81. Oncology, Oral – Breast – Truqap Tablet
82. Oncology, Oral – Hematologic - Ojjaara
83. Oncology, Oral – Lung – Augtyro Capsule
84. Oncology, Oral – Lung – Rozlytrek Pellet
85. Oncology, Oral – Lung – Xalkori Pellet
86. Oncology, Oral – Other - Fruzaqla
87. Oncology, Oral – Other – Iwilfin Tablet
88. Oncology, Oral – Other – Ogsiveo
89. Ophthalmics, Anti-Inflammatory/Immunomodulator – Vevye
90. Sickle Cell Anemia Treatments – Casgevy
91. Sickle Cell Anemia Treatments – Lyfgenia
92. Ophthalmics, Glaucoma Agents – Alphagan P 0.15%, 0.1%
93. Ophthalmics, Glaucoma Agents – Brimonidine 0.15%

IX. Other Changes

X. Other Business

XI. Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting

XII. Proposed Next Meeting Dates – Friday, October 25, 2024, Wednesday, October 30, 2024

XIII. Public Testimony